Life360 Inc (ASX: 360) shares are trading about 60% below where brokers think they should be, and the difference has a very specific cause.

The stock closed Wednesday at $19.64, whereas the average analyst target price is $31.72. Every broker covering the company rates it a buy or strong buy.

Why Life360 shares fell so far

The de-rating started well before the latest result.

The shares peaked at $55.44 in early October and then fell to an annual low of $17.91 by mid-April.

Most of that was sector-wide, as investors sold high-multiple technology names on fears that artificial intelligence could erode software business models.

ASX tech stocks then rallied through June and early August on a strong first quarter.

The second quarter update in mid-August ended that recovery, and the shares shed 30% of their value in the weeks that followed.

What the second quarter showed

Despite this pullback, second quarter numbers were at a record high.

Total revenue rose 38% year-on-year to US$159.0 million, and adjusted EBITDA increased 53% to US$31.1 million.

Annualised monthly revenue grew 29% to US$537.2 million and paying circles jumped 27% to 3.2 million.

Advertising revenue reached a record US$22 million, up 315%, while operating cash flow grew 79% to US$23.8 million.

Global monthly active users rose 4.6 million in the quarter to approximately 102.4 million.

Chief executive Lauren Antonoff framed the quarter around the user gowth milestone.

This quarter, Life360 crossed 100 million monthly active users—proof of the trust millions of families place in us to stay connected, coordinated, and safe. Disciplined execution drove strong Paying Circle growth and put MAU back on the growth trajectory we outlined last quarter.

However, operating expenses also rose 43% to US$127 million, largely on growth and integration costs from the Nativo acquisition.

The two details that sank the result

The first is guidance.

Life360 left FY26 revenue guidance at US$650 million to US$685 million and adjusted EBITDA at US$130 million to US$140 million.

Shareholders had grown used to upgrades, but received a reiteration instead.

The second is the quality of the earnings beat.

Bell Potter noted that paying circles grew by 185,000 against its 155,000 forecast and consensus of 136,000, and that adjusted EBITDA comfortably beat its US$25.7 million estimate.

Roughly US$4 million of that beat, however, came from a tariff refund.

Underlying adjusted EBITDA was therefore closer to US$27 million.

What brokers say Life360 shares are worth

Bell Potter kept its buy rating and trimmed its target slightly.

The net impact on our target price is a 3% decrease to $34.00 which has all been driven by the DCF due to modest downgrades and changes in working capital assumptions. We retain our BUY recommendation and note we expect the buyback to be more active this quarter after only modestly commencing last quarter.

Every analyst covering the company currently holds a buy or strong buy rating.

The $31.72 average target implies about 60% upside, and the most bullish sits above $40.

Foolish takeaway

The bull case for Life360 shares is that a company growing revenue at 38% should not trade on 25 times earnings.

The bear case is that the market no longer believes guidance will be beaten, and a tariff refund flatters the results.

I tend to agree more with the brokers than the share price, because paying circles and advertising are both compounding faster than the cost base.

In the short-term, however, Life360 shares will stay volatile until management either upgrades guidance or explains why it cannot.

The post Life360 shares are 60% below broker targets. Here’s why appeared first on The Motley Fool Australia.

More reading

• Top 3 ASX shares I’d buy after the most recent sell-off
• Brokers rate these 5 ASX shares as a strong buy, and tip upsides of 28% to 62%
• How to build a winning ASX share portfolio and create wealth
• Down 55%: Should I buy Life360 shares in September?
• Are these ASX tech stocks finally a buy again?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Buying an ASX share is easy. Finding one I would be comfortable leaving alone for many years is much harder.

For a genuine buy-and-hold investment, I want a strong business today with plenty of opportunity still ahead.

These three could be best buys for me.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is an ASX share that has already grown enormously, but I still think its best years could be ahead.

The healthcare technology company develops the Visage imaging platform used by hospitals and radiology groups to view and manage medical images.

Despite winning contracts with some of the United States’ largest hospital networks, management has previously estimated that Pro Medicus still holds only around 11% of the market.

That leaves a substantial number of hospitals still available to win.

There is also more to the opportunity than radiology. Pro Medicus is expanding further into cardiology and broader enterprise imaging, potentially allowing its software to become more deeply embedded across hospital systems.

Winning major healthcare customers can take time, but once the platform becomes central to clinical workflows, I think those relationships can be extremely valuable.

That makes Pro Medicus the type of business I would be comfortable holding through short-term share price volatility.

TechnologyOne Ltd (ASX: TNE)

TechnologyOne could also be one of the best ASX shares for a long holding period.

Its enterprise software is used by councils, universities, government organisations, and other large institutions to manage important day-to-day operations.

These customers generally do not change core software systems lightly. Moving financial, payroll, property, or other critical processes to another provider can be expensive and disruptive. That helps TechnologyOne build long customer relationships and recurring revenue.

I also like that the business still has opportunities outside Australia. Its expansion in the United Kingdom gives TechnologyOne another sizeable market to pursue, while continued investment in cloud software and artificial intelligence could increase the value of its products for existing customers.

Overall, I think TechnologyOne has many of the qualities I want from an ASX share I would own for a decade or longer.

REA Group Ltd (ASX: REA)

REA Group is another ASX share I would be comfortable owning for the long term.

Its realestate.com.au platform has become deeply embedded in how Australians search for property, giving the company a very strong position with both buyers and sellers.

That large audience is a major advantage. Property agents want to advertise where buyers are already looking, while buyers keep returning because that is where the listings are. I think that creates a network effect that is difficult for competitors to replicate.

The Australian housing market will always move through stronger and weaker periods, so listings activity can fluctuate.

But over a long timeframe, I think REA Group’s dominant position and ability to earn more from its audience give the business plenty of room to keep growing.

Foolish takeaway

I would not necessarily expect these ASX shares to outperform every year.

What I like is that each company has a strong position today and a clear opportunity to become much larger over the next decade.

If I could buy Pro Medicus, TechnologyOne, and REA Group at sensible valuations, I would be happy to hold them for years and give those growth stories time to develop.

The post Why I think these are the best ASX shares to buy and hold appeared first on The Motley Fool Australia.

More reading

• EchoIQ shares just crashed 48%. What happens now?
• Expert names 2 beaten-down ASX All Ords healthcare shares to buy today
• 7 ASX healthcare stock picks from Bell Potter
• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• 6 ASX shares tipped by brokers to rise 34% to 88%

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Uranium stocks have made headlines this week, with global tailwinds providing long-term upside for producers. 

In particular, Paladin Energy Ltd (ASX: PDN) has drawn significant attention from brokers.

Why the increased attention for uranium stocks?

As reported by my colleague Mark Verhoeven earlier this week, the spot price of uranium is hovering near US$90 a pound. 

However, more importantly, the long-term contract price is US$97 a pound, its highest level in more than eighteen years.

This is being driven by expectations of a gap between supply and demand. 

On the supply side, some of the world’s biggest uranium producers are facing production challenges and delays, making it harder to increase supply. 

At the same time, demand for uranium is expected to rise significantly as more countries build and rely on nuclear power. 

Utilities companies are already locking in uranium supplies years in advance because they want to make sure they have enough fuel for their reactors. 

If demand keeps growing while supply remains tight, uranium prices could stay strong or rise, which could benefit companies that produce or develop uranium projects. 

This is why investors are paying more attention to ASX-listed uranium stocks.

Why Paladin is a winner 

This is positive for Paladin Energy because it is already producing uranium through its Langer Heinrich mine in Namibia. 

If global uranium demand continues to rise while supply remains tight, uranium prices could increase, allowing the uranium stock to potentially generate more revenue and profits. 

In simple terms, it benefits if uranium becomes more valuable because it is already a producer and can sell into that stronger market.

Brokers tipping big upside 

Thanks to these emerging tailwinds, brokers are tipping healthy gains over the next 12 months for this ASX uranium stock. 

It closed trading yesterday at $11.73 per share. 

The team at Canaccord Genuity has a buy call on Paladin Energy shares with a $15.80 target.

This indicates a 34% upside from current levels. 

Elsewhere, Morgans has an accumulate rating and $13.30 price target, indicating 13% upside. 

The current Patterson Lake South (PLS) resource may only represent part of the story – The mine plan supports ~9Mlbpa over nine years, yet mineralisation remains open at depth and along strike, drilling density declines materially below 350m. We expect the resource and mine life to increase materially in time. Simply simple – PLS is one of the highest-grade undeveloped uranium projects globally, but its development plan is surprisingly conventional, with a TBM decline, proven mining methods, a standard Athabasca processing flowsheet and uncomplicated tailings storage reducing technical risk.

The post Brokers are confident in the outlook for this uranium stock tipping 34% upside appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• 6 ASX shares tipped by brokers to rise 34% to 88%
• Uranium is back. Three ASX shares that give you exposure
• These are the 10 most shorted ASX shares
• 9 ASX shares downgraded by experts post-results this week

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.